In a report released on August 7, Puneet Souda from Leerink Partners maintained a Buy rating on Myriad Genetics (MYGN – Research Report), with a price target of $35.00. Puneet Souda has given his Buy ...
These mutations improve biocontainment, transformation stability, and overall performance in genetic engineering of plants. Complementing the strains, researchers also developed new plasmids and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback